Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer.
about
New targets for therapy in breast cancer: farnesyltransferase inhibitors.Association of the breast cancer antiestrogen resistance protein 1 (BCAR1) and BCAR3 scaffolding proteins in cell signaling and antiestrogen resistanceModeling of tumor progression in NSCLC and intrinsic resistance to TKI in loss of PTEN expressionRelationships between signaling pathway usage and sensitivity to a pathway inhibitor: examination of trametinib responses in cultured breast cancer linesPhosphorylation state-specific antibodies: applications in investigative and diagnostic pathology.Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells.Genomics of signaling crosstalk of estrogen receptor alpha in breast cancer cells.Epidermal growth factor receptor signalling in human breast cancer cells operates parallel to estrogen receptor α signalling and results in tamoxifen insensitive proliferationMicroRNA-382-5p aggravates breast cancer progression by regulating the RERG/Ras/ERK signaling axis.Progesterone and breast cancer.Mechanisms of disease: epithelial-mesenchymal transition--does cellular plasticity fuel neoplastic progression?Associations between clinicopathological prognostic factors and pAkt, pMAPK and topoisomerase II expression in breast cancer.Boswellia sacra essential oil induces tumor cell-specific apoptosis and suppresses tumor aggressiveness in cultured human breast cancer cells.Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells.Low ERK phosphorylation in cancer-associated fibroblasts is associated with tamoxifen resistance in pre-menopausal breast cancer.Integrated quantitative analysis of the phosphoproteome and transcriptome in tamoxifen-resistant breast cancer.Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapyGlobal characterization of signalling networks associated with tamoxifen resistance in breast cancer.Metabotropic glutamate receptor 1 expression and its polymorphic variants associate with breast cancer phenotypes.Protein kinase D1 regulates ERα-positive breast cancer cell growth response to 17β-estradiol and contributes to poor prognosis in patientsEndocrine-responsive breast cancer and strategies for combating resistance.Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer.Clinical significance of pAkt and pErk1/2 expression in early-stage breast cancer patients treated with anthracycline-based adjuvant chemotherapy.Complex prolactin crosstalk in breast cancer: new therapeutic implicationsUnraveling heterogeneous susceptibility and the evolution of breast cancer using a systems biology approachNew insights into estrogen receptor function in human breast cancer.A role for estrogen receptor phosphorylation in the resistance to tamoxifen.Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen.Growth factor-induced resistance to tamoxifen is associated with a mutation of estrogen receptor alpha and its phosphorylation at serine 305.Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance3D culture of Her2+ breast cancer cells promotes AKT to MAPK switching and a loss of therapeutic response.High ERK protein expression levels correlate with shorter survival in triple-negative breast cancer patientsSystematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancerProtein kinase C isoform expression as a predictor of disease outcome on endocrine therapy in breast cancerInsulin-like growth factor 1 attenuates antiestrogen- and antiprogestin-induced apoptosis in ER+ breast cancer cells by MEK1 regulation of the BH3-only pro-apoptotic protein BimPhosphoproteomic Analysis Identifies Focal Adhesion Kinase 2 (FAK2) as a Potential Therapeutic Target for Tamoxifen Resistance in Breast Cancer.MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft ModelHeregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.Phosphorylation at serines 104 and 106 by Erk1/2 MAPK is important for estrogen receptor-alpha activity.Expression and prognostic relevance of activated extracellular-regulated kinases (ERK1/2) in breast cancer.
P2860
Q24796277-D0B40103-BFA9-4ECF-A047-B69EB8EACD03Q28308160-239AE4D8-A0D6-4488-8DAE-72C38604F962Q28484612-E3EE8C45-777A-4D0E-8009-7E4E147F5A0CQ28542662-1BC592AA-D82F-4111-BB33-2456BAA374D3Q30311912-2D18E314-D40E-4E0B-B950-0D14ECB5B80BQ30441321-729E97F7-46F2-4A7A-835C-F27C10F7D5C3Q33325484-DE8C4328-C813-4E20-89A3-C6C1614E628DQ33612070-C29CDA00-2806-421B-8E5E-6AC16FC6D916Q33618363-A27887F9-F7A8-4478-AD7E-0E942F754BC6Q33687459-15C8E30D-0D5C-4DF8-9B05-331BDDC47D7EQ33755906-0C2B7150-F9F1-428F-BB7D-E8D9ED204705Q33816025-B96C1323-F938-4392-A384-941448AC33ACQ34101905-CA53BC29-F256-4448-BF02-99255D96224CQ34369138-278DD2B4-7072-4CEE-9B4D-64153662830FQ34429766-DE62320A-293C-479D-9DA4-729AC94F7047Q34452797-0D1299E5-5924-43F4-868E-567B64CFCBD2Q34480666-A3EF531B-36F0-4BA3-A3BB-7B4E0CC89146Q34857146-4C04FD77-7BE0-49CF-893E-A1DDBBD6C1A1Q34904277-4B04A485-1925-48A6-89CA-324635DF45F9Q34998421-B77186A9-32BE-46BB-99CE-DDC74BB66102Q35084786-5D040D27-D200-4EC8-98F3-750251394A62Q35118166-3C47BD00-EEDD-4849-B6E4-79A6571DB9A7Q35167772-7B6AE009-7C26-4F0B-ADF7-D41AD9231A8BQ35303180-9D07C206-7948-450E-A6BD-AA0864FF0369Q35312645-1F37B5CC-0DEA-404F-8BDD-8033A4BD02C7Q35622050-B3AEE4BB-453E-44E3-B491-1B36BD44FFD1Q35684445-9D0E4942-5C71-4B0F-9D0B-1B811437ABC1Q35779181-5D95DBE0-CE5C-4AA9-89CD-8A813D277EB7Q35786706-F9D46E8A-0A27-4035-9AE4-3B920C4132A4Q35795153-0428FFF9-8332-45E8-AE10-8A33A490F126Q36037262-5DC558BB-80FB-4A64-8F29-7BE077F52564Q36051484-41786367-0040-4057-9589-B2DF0A663ED4Q36067934-E7F4AD42-CF52-43CF-BDEA-B6A4421FB482Q36172210-DFFB5A8D-45AD-46BA-95AA-89111F5C4D69Q36245560-536469FC-9526-43CB-A433-3235BEE82B0CQ36263003-47792771-92B8-4F4F-A1D6-0B785473C6F1Q36359541-40BFAE53-3C50-4EED-9C4A-EF25693C2CFCQ36393289-36129153-C470-42F1-BA91-39F1A59DF274Q36514584-6663E6DC-6891-4EA4-9D48-A073481E2254Q36616070-C3B2E3E0-0C5D-4658-AAE1-25AF079E35C6
P2860
Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Phosphorylation of ERK1/2 mito ...... val in clinical breast cancer.
@en
Phosphorylation of ERK1/2 mito ...... val in clinical breast cancer.
@nl
type
label
Phosphorylation of ERK1/2 mito ...... val in clinical breast cancer.
@en
Phosphorylation of ERK1/2 mito ...... val in clinical breast cancer.
@nl
prefLabel
Phosphorylation of ERK1/2 mito ...... val in clinical breast cancer.
@en
Phosphorylation of ERK1/2 mito ...... val in clinical breast cancer.
@nl
P2860
P1476
Phosphorylation of ERK1/2 mito ...... val in clinical breast cancer.
@en
P2093
J F Robertson
R I Nicholson
P2860
P304
P356
10.1002/1097-0215(20010720)95:4<247::AID-IJC1042>3.0.CO;2-S
P577
2001-07-01T00:00:00Z